Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study
Hepatology Research · 2026-08 · 56 (8) · 1191-1201
DOI: 10.1111/hepr.70172 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Hepatology Research, online erschienen am 01.04.2026. Verfasst von Satoru Kakizaki und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Sofosbuvir/velpatasvir (SOF/VEL) treatment for hepatitis C virus (HCV)–related decompensated cirrhosis has been shown to achieve a high sustained virologic response (SVR) rate and to improve liver function. However, limited data are available regarding the association between improvements in liver function and long‐term survival. This multicenter study aimed to evaluate longitudinal changes in liver function and factors associated with long‐term prognosis in patients treated with SOF/VEL.
Methods
Ninety‐one patients who received SOF/VEL for HCV‐related decompensated cirrhosis between March 2019 and December 2021 were enrolled. SVR rates, changes in Child–Pugh scores at 12, 24, 48, 72, and 120 weeks after treatment, changes in albumin–bilirubin (ALBI) scores, and overall survival (OS) were assessed. The impact of post‐treatment ALBI improvement on prognosis was examined, and its predictive ability for 60‐month OS was evaluated using receiver operating characteristic analysis. Survival was compared using the Kaplan–Meier method.
Results
The median age was 68.0 years; 36.3% of patients were male, and 24.2% had a history of hepatocellular carcinoma. SVR was achieved in 96.7% of patients. The median observation period was 57.0 months (IQR, 43.0–72.0), and 27 patients (29.7%) died during the observation period. Child–Pugh scores improved from the end of treatment and continued to improve; at 120 weeks, 55.9% of patients had scores of 5 or 6. The median OS was not reached, and the 5‐year survival rate was 73.2%. ALBI improvement predicted 60‐month OS with a sensitivity of 0.494, a specificity of 0.851, and an optimal cutoff value of a decrease in ALBI score of ≥ 0.103. Patients with ALBI improvement showed significantly better OS.
Conclusions
SOF/VEL therapy achieved high SVR rates and demonstrated that post‐treatment improvement in the ALBI score is strongly associated with a favorable long‐term prognosis in patients with decompensated cirrhosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
- Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.
- Department of Gastroenterology, Ibaraki Medical Center, Tokyo Medical University, Ami, Japan.
- Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
- Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi, Japan.
- Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Japan.
ORCID-Profile: Satoru Kakizaki, Tadashi Ikegami, Takeshi Hatanaka, Atsushi Naganuma, Toshiro Kamoshida, Takayoshi Suga, Satoshi Takakusagi, Hitoshi Takagi, Yuki Kanayama, Hiroki Tojima, Yuichi Yamazaki, Kouichi Miura, Naoki Morimoto
Zitieren
APA
Kakizaki, S., Ikegami, T., Hatanaka, T., Suzuki, Y., Hoshino, T., Naganuma, A., Takizawa, D., Arai, H., Ueno, T., Iizuka, K., Arisaka, T., Majima, Y., Iijima, M., Tano, S., Tahara, T., Araki, M., Kamoshida, T., Takaoka, Y., Kurata, H., …, & Liver Investigators in the Northern Kanto Study (LINKS) group (2026). Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study. Hepatology Research, 56(8), 1191-1201. https://doi.org/10.1111/hepr.70172
Vancouver
Kakizaki S, Ikegami T, Hatanaka T, Suzuki Y, Hoshino T, Naganuma A, et al. Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study. Hepatology Research. 2026;56(8):1191-1201. doi:10.1111/hepr.70172
BibTeX
@article{Kakizaki2026,
author = {Kakizaki, Satoru and Ikegami, Tadashi and Hatanaka, Takeshi and Suzuki, Yuhei and Hoshino, Takashi and Naganuma, Atsushi and Takizawa, Daichi and Arai, Hirotaka and Ueno, Takashi and Iizuka, Keisuke and Arisaka, Takahiro and Majima, Yuichi and Iijima, Makoto and Tano, Shigeo and Tahara, Toshiyuki and Araki, Masahiro and Kamoshida, Toshiro and Takaoka, Yoshinari and Kurata, Hidekazu and Fukaya, Yukimura and Fukuda, Kuniaki and Soeda, Atsuko and Suga, Takayoshi and Saito, Shuichi and Fukuchi, Toru and Takakusagi, Satoshi and Takagi, Hitoshi and Horiuchi, Katsuhiko and Kanayama, Yuki and Ohtake, Toshiya and Tojima, Hiroki and Yamazaki, Yuichi and Watanabe, Shunji and Miura, Kouichi and Morimoto, Naoki and Liver Investigators in the Northern Kanto Study (LINKS) group, Liver Investigators in the Northern Kanto Study (LINKS) group},
title = {Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {8},
pages = {1191--1201},
doi = {10.1111/hepr.70172}
}
EUVIMED